These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1296 related items for PubMed ID: 25127748

  • 21. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals.
    Hopkins S, Lambourne J, Farrell G, McCullagh L, Hennessy M, Clarke S, Mulcahy F, Bergin C.
    HIV Med; 2006 May; 7(4):248-54. PubMed ID: 16630037
    [Abstract] [Full Text] [Related]

  • 22. Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection.
    Lin TY, Yeh ML, Huang CI, Chen YL, Dai CY, Huang JF, Lin ZY, Chen SC, Huang CF, Yu ML, Chuang WL.
    Kaohsiung J Med Sci; 2017 Jun; 33(6):284-289. PubMed ID: 28601232
    [Abstract] [Full Text] [Related]

  • 23. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.
    Acta Biochim Pol; 2012 Jun; 59(3):333-7. PubMed ID: 22924160
    [Abstract] [Full Text] [Related]

  • 24. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
    Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourlière M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM, ANRS HC27 BOCEPREVIH Study Group.
    HIV Clin Trials; 2016 Mar; 17(2):63-71. PubMed ID: 27077673
    [Abstract] [Full Text] [Related]

  • 25. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA, Mira JA, Gil Ide L, Valera-Bestard B, Rivero A, Merino D, Girón-González JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Carrillo-Gómez R, López-Cortés LF, Gómez-Mateos J.
    J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
    [Abstract] [Full Text] [Related]

  • 26. The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study.
    Ferreira PR, Silva MH, Brandão-Melo CE, Rezende RE, Gonzalez M, Reuter T, Urbaez JD, Gianini RJ, Martinelli A, Mendes-Correa MC.
    Braz J Infect Dis; 2015 Dec; 19(1):15-22. PubMed ID: 25181403
    [Abstract] [Full Text] [Related]

  • 27. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
    Aziz H, Raza A, Waheed Y, Gill U, Gill ML.
    Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
    [Abstract] [Full Text] [Related]

  • 28. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
    Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M.
    Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
    [Abstract] [Full Text] [Related]

  • 29. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus.
    Yu JW, Sun LJ, Zhao YH, Kang P, Gao J, Li SC.
    Liver Int; 2009 Nov; 29(10):1485-93. PubMed ID: 19602134
    [Abstract] [Full Text] [Related]

  • 30. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P, Italian Co-infection Study (ICOS) Group.
    Antivir Ther; 2005 Nov; 10(2):309-17. PubMed ID: 15865225
    [Abstract] [Full Text] [Related]

  • 31. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [Abstract] [Full Text] [Related]

  • 32. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, Shebl FM, Amer AM, Butt MT, Yakoob R, John A, Al Mohanadi M, Al Khinji MA.
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [Abstract] [Full Text] [Related]

  • 33. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V, PERICO Study Group.
    J Infect Dis; 2012 Sep 15; 206(6):961-8. PubMed ID: 22807523
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF, Fernández-Carbia A, González-Lassalle E, Salgado-Mercado R, Marxuach-Cuétara AM.
    J Clin Virol; 2007 Jan 15; 38(1):32-8. PubMed ID: 17064957
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
    Faisal N, Mumtaz K, Marquez M, Renner EL, Lilly LB.
    Hepatol Int; 2015 Jan 15; 9(1):76-83. PubMed ID: 25788382
    [Abstract] [Full Text] [Related]

  • 37. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
    Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT.
    Int J Artif Organs; 2008 Apr 15; 31(4):295-302. PubMed ID: 18432584
    [Abstract] [Full Text] [Related]

  • 38. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.
    Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL, Falco V, Quer J, Ocaña I, Ruiz I, Buti M, Pahissa A, Esteban R, Guardia J.
    J Viral Hepat; 2007 Apr 15; 14(4):228-38. PubMed ID: 17381714
    [Abstract] [Full Text] [Related]

  • 39. Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review.
    Wells MM, Roth LS, Marotta P, Levstik M, Mason AL, Bain VG, Chandok N, Aljudaibi BM.
    Saudi J Gastroenterol; 2013 Apr 15; 19(5):223-9. PubMed ID: 24045596
    [Abstract] [Full Text] [Related]

  • 40. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C.
    Núnez M, Camino N, Ramos B, Berdún MA, Barreiro P, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Martín-Carbonero L, Romero M, García-Samaniego J, Soriano V.
    Antivir Ther; 2005 Apr 15; 10(5):657-62. PubMed ID: 16152759
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 65.